Abstract
Soluble amyloid β (Aβ) oligomers might trigger early cognitive deficit in Alzheimers Disease (AD) through the impairment of proper neuronal network function. We have recently shown that the short sequence Aβ25-35 affects the spontaneous activity in hippocampal slices, when was added to the bath, at high nanomolar concentrations. In the present study, we aimed to characterize the effects of the oligomerized full length sequence Aβ1-42 on the spontaneous network activity in the CA1 hippocampal area testing whether such effects are age dependent. By performing extracellular field recordings of spontaneous network activity of hippocampal slices, we found that an oligomerized solution of Aβ1-42 (osAβ) potently inhibit, in a dose-dependent manner, the spontaneous hippocampal network activity with an IC50 of 0.4 ± 3.2 nM and a maximal effect reached around 10 nM. While spontaneous hippocampal network activity is unaffected by age, the sensitivity of spontaneous hippocampal network activity to osAβ (10 nM) appears to be increased in slices from older animals. Moreover, to see a significant reduction in spontaneous network activity in slices from animals in their second week of life 100nM osAβ was needed. The osAβ-induced reduction in hippocampal network activity is accompanied by a presynaptic reduction in both spontaneous and miniature synaptic potentials. Finally, we demonstrated that the effect produced by osAβ on spontaneous network activity was specific, reversible and unrelated with cell death. In conclusion, our data show that osAβ alters hippocampal network activity at concentrations commonly observed in AD patients and that such effect of osAβ increases with age.
Keywords: Alzheimer's disease, amyloid β oligomers, hippocampal spontaneous activity, age
Current Alzheimer Research
Title: Amyloid β Oligomers Decrease Hippocampal Spontaneous Network Activity in an Age-Dependent Manner
Volume: 7 Issue: 5
Author(s): H. Balleza-Tapia, A. Huanosta-Gutierrez, A. Marquez-Ramos, N. Arias and F. Pena
Affiliation:
Keywords: Alzheimer's disease, amyloid β oligomers, hippocampal spontaneous activity, age
Abstract: Soluble amyloid β (Aβ) oligomers might trigger early cognitive deficit in Alzheimers Disease (AD) through the impairment of proper neuronal network function. We have recently shown that the short sequence Aβ25-35 affects the spontaneous activity in hippocampal slices, when was added to the bath, at high nanomolar concentrations. In the present study, we aimed to characterize the effects of the oligomerized full length sequence Aβ1-42 on the spontaneous network activity in the CA1 hippocampal area testing whether such effects are age dependent. By performing extracellular field recordings of spontaneous network activity of hippocampal slices, we found that an oligomerized solution of Aβ1-42 (osAβ) potently inhibit, in a dose-dependent manner, the spontaneous hippocampal network activity with an IC50 of 0.4 ± 3.2 nM and a maximal effect reached around 10 nM. While spontaneous hippocampal network activity is unaffected by age, the sensitivity of spontaneous hippocampal network activity to osAβ (10 nM) appears to be increased in slices from older animals. Moreover, to see a significant reduction in spontaneous network activity in slices from animals in their second week of life 100nM osAβ was needed. The osAβ-induced reduction in hippocampal network activity is accompanied by a presynaptic reduction in both spontaneous and miniature synaptic potentials. Finally, we demonstrated that the effect produced by osAβ on spontaneous network activity was specific, reversible and unrelated with cell death. In conclusion, our data show that osAβ alters hippocampal network activity at concentrations commonly observed in AD patients and that such effect of osAβ increases with age.
Export Options
About this article
Cite this article as:
Balleza-Tapia H., Huanosta-Gutierrez A., Marquez-Ramos A., Arias N. and Pena F., Amyloid β Oligomers Decrease Hippocampal Spontaneous Network Activity in an Age-Dependent Manner, Current Alzheimer Research 2010; 7 (5) . https://dx.doi.org/10.2174/156720510791383859
DOI https://dx.doi.org/10.2174/156720510791383859 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuropsychiatric Disturbances in Alzheimer’s Disease: What Have We Learned from Neuropathological Studies?
Current Alzheimer Research 5-ht6 Receptors
Current Drug Targets - CNS & Neurological Disorders Aspartate and Glutamate Mimetic Structures in Biologically Active Compounds
Current Medicinal Chemistry Common Mechanisms of Excitatory and Inhibitory Imbalance in Schizophrenia and Autism Spectrum Disorders
Current Molecular Medicine Brain Tumor-Related Epilepsy
Current Neuropharmacology Pediatric Catatonia: Updating An Old Syndrome in Young People
Current Psychiatry Reviews Xenobiotic Acyl Glucuronides and Acyl CoA Thioesters as Protein- Reactive Metabolites With the Potential to Cause Idiosyncratic Drug Reactions
Current Drug Metabolism Affective Disorder and Hyperandrogenism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Astroglial Connexins in Neurological and Neuropsychological Disorders and Radiation Exposure
Current Medicinal Chemistry Editorial (Thematic Issue: Global Trends for Nanotechnological Approaches in Various Health Issues - Part 1)
Current Drug Metabolism Ethanolamine: A Potential Promoiety with Additional Effects on the Brain
CNS & Neurological Disorders - Drug Targets Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
Current Cardiology Reviews The Clinical Difference between Gabapentin and Pregabalin: Data from a Pilot Comparative Trial
Reviews on Recent Clinical Trials The Effects of Soluble Aβ Oligomers on Neurodegeneration in Alzheimer's Disease
Current Pharmaceutical Design Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design GABA Transporters and GABA-Transaminase as Drug Targets
Current Drug Targets - CNS & Neurological Disorders Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases
Current Medicinal Chemistry Sugar Sulfamates for Seizure Control: Discovery and Development of Topiramate, a Structurally Unique Antiepileptic Drug
Current Topics in Medicinal Chemistry Modulators of Voltage-Dependent Calcium Channels for the Treatment of Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued)